E
MLTX icon

Ergoteles’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ergoteles’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-38,617
Closed -$1.97M – 534
2023
Q2 		$1.97M Buy
+38,617
New +$1.04M 0.09% 275
2022
Q2 		– Sell
-14,613
Closed -$162K – 1861
2022
Q1 		$162K Buy
+14,613
New +$145K 0.01% 1041

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ergoteles's MLTX Position: Q3 2023 in Review

Ergoteles sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2023, closing a stake of 38,617 shares — an estimated $1.97M sold.

Ergoteles first reported a position in MLTX in Q1 2022 and held it in 2 quarters. The position peaked at $1.97M in Q2 2023. 118 funds tracked by Wall St. Rank hold MLTX as of Q3 2023.

  • Ergoteles reported no remaining MoonLake Immunotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 38,617 MoonLake Immunotherapeutics shares in Q3 2023, an estimated $1.97M.
  • Ergoteles first reported a position in MoonLake Immunotherapeutics in Q1 2022 and held it in 2 quarters.
  • Ergoteles's MoonLake Immunotherapeutics position peaked at $1.97M in Q2 2023.
  • 118 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.